Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...
In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights increased data management, DE&I, and ...
Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...
Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...
In the Phase I dose escalation portion, which evaluated the combination in participants with small cell lung cancer, the first patient treated attained partial remission.
Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.
In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, looks back to 2024 and discusses some of the industry’s ...
End-to-end offering is designed to streamline site activation and optimize visibility in critical research processes.
Use of decentralized approach in a Phase 1 pharmacokinetic trial shows the ability to enable remote data collection and ...
In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights how artificial intelligence, real-time monitoring, and historical data can aid in optimizing trial design.
Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...
Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback